Hemostemix Stock Price, News & Analysis

Hemostemix (OTCQB: HMTXF) announced a significant financial restructuring, with Chairman Peter Lacey providing a $1.5 million lead order for a non-brokered private placement at $0.10 per Unit. Each Unit includes one Common Share and one Warrant exercisable at $0.15 for two years. $1.25 million will be used to fully repay a $2.5 million Convertible Debenture.

The placement is part of a larger offering totaling up to $2.5 million. The company also confirmed the conversion price of previously announced ACP-01 Therapy Convertible Debentures (TCD) at CAD $0.155, relating to the March 5 sale of 15 TCDs for $708,605.

Hemostemix (HMTXF) has closed a non-brokered private placement raising CAD $469,366 through the issuance of 3,911,385 common shares at CAD $0.12 per share, pending TSXV Exchange approval. The securities will have a four-month hold period from closing. The proceeds will support general working capital, operational expenses, and business development. Hemostemix is an autologous stem cell therapy company that has developed ACP-01, a blood-based stem cell therapy. The company has completed seven clinical studies with 318 subjects, with results published in nine peer-reviewed publications. Their Phase II clinical trial for chronic limb threatening ischemia showed promising results, including 0% mortality and 83% wound healing in patients followed for up to 4.5 years.

Hemostemix Inc. (HMTXF) presented its clinical trial results at the TERMIS 2025 World Congress in Freiburg, Germany. The company showcased its Phase II clinical trial findings, published in JBRES, demonstrating significant improvements in ischemic tissue perfusion, pain reduction, wound healing, and limb salvage in no-option CLTI patients. The presentation also highlighted data from five heart studies investigating ACP-01 in various cardiac conditions.

CEO Thomas Smeenk emphasized the company's revenue generation of >$1 Million to date and discussed their strategy of using therapy convertible debentures sales to fund their phase III clinical trial. The company's autologous blood-based stem cell therapy, ACP-01, has completed seven clinical studies with 318 subjects, showing promising results for various cardiovascular conditions, with notably 0% mortality and 83% wound healing rates in CLTI patients.

Hemostemix (OTCQB: HMTXF) has completed a non-brokered private placement of USD $336,500, issuing 1,634,466 common shares at CAD $0.295 per share to CytoImmune Therapeutics LLC. The proceeds will be used for general working capital and business development activities.

The company is an autologous stem cell therapy platform developer that has completed seven clinical studies involving 318 subjects. Their lead product, ACP-01, has shown significant results in treating various conditions including peripheral arterial disease and chronic limb threatening ischemia (CLTI). Notable results from their Phase II CLTI trial showed 0% mortality and wound healing in 83% of patients, compared to the typical 60% five-year mortality rate.

[ "Successful completion of USD $336,500 private placement for working capital", "Strong clinical trial results with 0% mortality rate in CLTI patients vs. industry standard 60%", "83% success rate in wound healing for patients followed up to 4.5 years", "Extensive clinical experience with 7 completed studies involving 318 subjects" ]

Hemostemix Inc. (HMTXF) will participate in Invest Stuttgart 2025, Germany's leading finance and investment conference, from May 9-10, 2025. The company specializes in autologous stem cell therapies, with its flagship product ACP-01 treating various cardiovascular conditions. The therapy has demonstrated safety and efficacy across 498 patients and seven clinical studies.

The company has introduced ACP-01 Therapy Convertible Debentures (TCDs) as an innovative financing instrument, offering 6% annual interest payable in shares. TCDs can be converted into either ACP-01 therapy or common shares. Hemostemix has already sold over CAD $1.14 million of TCDs, supporting revenue forecasting and treatment scheduling.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) has partnered with PatentVest, a subsidiary of MDB Capital, to strengthen its global patent portfolio in autologous stem cell therapy for cardiovascular diseases. PatentVest will provide comprehensive IP support including:

• Evaluation and optimization of existing patents
• Identification of new patentable therapeutic innovations
• Development of global filing strategies
• Enhancement of company value for strategic partnerships

PatentVest will accept partial payment in equity, aligning with shareholder interests. The partnership aims to extend patent terms based on ongoing FDA studies and leverage the company's automated bioreactor technology license to reduce production costs and improve treatment accessibility.

Hemostemix (HMTXF) has announced a Phase 1 clinical trial for treating Vascular Dementia with ACP-01, targeting up to 100 patients. Each patient will pay USD $37,000 for the treatment, potentially generating USD $3.7M (CAD $5.36M) in revenue.

The trial will evaluate the safety, tolerability, and preliminary efficacy of intrathecal ACP-01 injection directly into cerebrospinal fluid. Primary endpoints include safety assessment and ACP-01 delivery feasibility, while secondary endpoints focus on cognitive function, dementia rating, and quality of life measurements.

The study will utilize FireFly's BNA™ technology for brain activity monitoring, comparing results against their FDA-cleared database of 77,000 EEG brain scans. The company reports a successful case study of a patient treated with ACP-01 showing positive results 10 years post-treatment.

Hemostemix (TSXV: HEM) and Firefly Neuroscience (NASDAQ: AIFF) have announced a collaboration to conduct a Phase 1 clinical trial studying ACP-01 as a treatment for vascular dementia. The trial will evaluate brain wave activity in up to 100 patients using Firefly's FDA-Cleared BNA™ platform.

The study will assess patients before treatment and at 3 and 6-month intervals post-treatment. Hemostemix will leverage Firefly's database of 77,000 EEG brain scans across twelve disorders. The trial's primary endpoints include safety assessment, ACP-01 delivery feasibility via intrathecal injection, dosage safety, and tolerability.

Secondary endpoints encompass cognitive functional assessment, clinical dementia rating, quality of life assessment, and MRI analyses of brain volume and blood flow. The exploratory endpoint will use Firefly's BNA™ readout at specified intervals to objectively evaluate ACP-01's efficacy in treating vascular dementia.

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) announces the sale of 15 ACP-01 Therapy Convertible Debentures for USD $517,230, pending TSXV Exchange approval. Year-to-date forward sales total CAD $1,149,983, providing non-dilutive working capital.

The company's production capacity is scaling from 20 to 40 treatments per month, and from 40 to 80 treatments monthly. At 20 treatments per month, annual revenue potential is USD $8,880,000 (CAD $12,876,000), with potential to quadruple with one physician performing four blood draws daily.

Each ACP-01 therapy convertible debenture (TCD) is unsecured, convertible into therapy on first-purchased basis, transferable, and earns 6% annual interest payable in shares. TCDs may be listed for trading in the future.